NEW YORK, Nov. 28 – Invitrogen has acquired the exclusive rights to develop and market genotyping products utilizing Orchid’s SNP-scoring primer extension technology in a 96-well format, the companies said Wednesday.

Under the terms of the deal, Invitrogen of San Diego will pay Orchid of Princeton, NJ, a royalty on kit sales. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.